(Q33397545)

26 July 2017

title

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

1

David A Reardon

1 reference

26 July 2017

2

Timothy Cloughesy

1 reference

26 July 2017

3

Jeremy Rich

1 reference

26 July 2017

W K Alfred Yung

4

1 reference

26 July 2017

Lotus Yung

5

1 reference

26 July 2017

Clifford DiLea

6

1 reference

26 July 2017

Jerry Huang

7

1 reference

26 July 2017

Margaret Dugan

8

1 reference

26 July 2017

William Mietlowski

9

1 reference

26 July 2017

Andrea Maes

10

1 reference

26 July 2017

Charles Conrad

11

1 reference

26 July 2017

publication date

9 October 2011

1 reference

Cancer Chemotherapy and Pharmacology

26 July 2017

published in

1 reference

26 July 2017

volume

69

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

281-287

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-011-1754-1

26 July 2017

exact match

0 references

cites work

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Review of the proliferation inhibitor everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Dose‐Finding with Two Agents in Phase I Oncology Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Cancer phase I clinical trials: efficient dose escalation with overdose control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1754-1

10.1007/S00280-011-1754-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1009222974

0 references

1 reference